The Bristol Myers Squibb-Pfizer Alliance on Friday announced it is partnering with Mark Cuban’s online pharmacy CostPlusDrugs.com to offer the prescription blood thinner Eliquis (apixaban) directly to patients at a significantly reduced cost.
Eliquis, one of the most widely prescribed anticoagulants in the U.S., is manufactured and marketed through a collaboration between Bristol Myers Squibb and Pfizer. Beginning Monday, April 27, Eliquis will be available on Cuban’s CostPlusDrugs.com for $346 for a 30-day supply.
The average retail pharmacy price for Eliquis is $520 to $800 per month for patients without insurance or discount cards.
Teaming up with Cost Plus Drugs provides another option for cash-paying patients to access Eliquis directly. This follows the 2025 launch of a direct-to-patient offering through the BMS-Pfizer Alliance’s patient resource Elliquis 360 Support, which is also accessible via BMS Patient Connect.
“The BMS-Pfizer Alliance is pleased to expand our direct-to-patient options for accessing Eliquis — a medicine relied upon by millions of Americans daily — to the popular Cost Plus Drugs platform,” said Adam Lenkowsky, chief commercial officer, Bristol Myers Squibb.
“This new collaboration is grounded in a shared commitment to transparency and offers another meaningful solution to overcome access barriers, lower costs and broaden the availability of our medicines for the patients who need them,” he said.
Mark Cuban, co-founder, Cost Plus Drugs said, “We’ve heard from a lot of people asking for Eliquis on Cost Plus Drugs, and this is about making sure they have a clearer, more direct way to access it. People shouldn’t have to guess what they’re going to pay for a medication they depend on. When you strip away the layers that drive up costs, you give people more control over how they get their prescriptions.”
Eliquis is an important treatment option for patients with atrial fibrillation (AFib), not caused by a heart valve problem, to reduce the risk of stroke and blood clots, as well as to treat blood clots in the veins of the legs or lungs and reduce the risk of them recurring. For every 100,000 patients treated, Eliquis has resulted in an estimated $3 billion in total healthcare cost savings and avoidance, such as hospitalization and extended rehabilitation needs, according to BMS.
